Tysabri and PML: What Ohio Clinicians Should Document

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Specific Exposure Risks

If you are a clinician treating a patient on Tysabri who develops new neurological symptoms, timing and documentation are critical. The medical literature has long established that early recognition of progressive multifocal leukoencephalopathy (PML) can improve outcomes, yet real-world reporting often lags. This page reviews what current reports say about symptom presentation, onset patterns, and documentation best practices for Ohio providers.

Medical Background and Clinical Presentation of PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Ohio who have developed PML after Tysabri treatment, understanding the medical evidence, risk factors, and legal considerations—including the statute of limitations—is essential. PML is an opportunistic viral infection of the brain caused by the JC virus, typically occurring only in immunocompromised individuals, and it usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation varies but commonly includes progressive neurological deficits such as weakness, cognitive decline, visual disturbances, ataxia, and speech difficulties. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid via PCR, often supported by brain biopsy. Early recognition is critical because Tysabri dosing should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Pharmacology and Risk Factors for Tysabri-Associated PML

Tysabri is a monoclonal antibody that binds to alpha-4 integrin, preventing immune cell migration into the central nervous system. This mechanism reduces inflammation in multiple sclerosis but also impairs immune surveillance, allowing JC virus reactivation. Three established risk factors increase PML risk in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond 2 years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Adequacy of Warnings and Regulatory Context

The prescribing information for Tysabri includes a boxed warning stating that Tysabri increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning emphasizes that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML and withhold Tysabri immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the risk of PML, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients must be enrolled in this program, read the Medication Guide, understand the risks, and complete and sign the Patient Enrollment Form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, questions may arise about whether the risks were adequately communicated to patients and whether earlier detection could have altered outcomes.

Statute of Limitations and Settlement Considerations for Ohio Patients

For patients in Ohio who have developed PML after Tysabri treatment, settlement considerations involve evaluating the timeline between exposure and documented harm, the adequacy of warnings provided, and the specific risk factors present. The statute of limitations for product liability claims in Ohio is generally two years from the date the injury was discovered or should have been discovered. Given that PML symptoms may develop gradually and diagnosis can be delayed, the discovery date is critical. Patients should document the date of first symptoms, the date of PML diagnosis, and the duration of Tysabri therapy. The presence of anti-JCV antibodies, treatment duration beyond two years, and prior immunosuppressant use are key factors that may influence risk assessment and settlement value. The onset of PML after Tysabri initiation can vary widely, ranging from a few months to several years. The risk increases with longer treatment duration, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For patients who develop PML, the harm is often severe and irreversible, leading to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Early detection through MRI and CSF analysis is crucial, but even with prompt diagnosis, outcomes remain poor. The timeline from exposure to harm is a central element in legal claims, as it establishes causation and the window for filing.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri PML claims in Ohio?

In Ohio, the statute of limitations for product liability claims is generally two years from the date the injury was discovered or should have been discovered. For Tysabri-associated PML, this means the clock starts when the patient knew or reasonably should have known that their PML was linked to Tysabri. Given the gradual onset of symptoms, it is crucial to document the date of first symptoms and the date of formal diagnosis to preserve the claim.

What are the key risk factors for developing PML while on Tysabri?

Three established risk factors increase PML risk in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond 2 years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

How is PML diagnosed in patients who have taken Tysabri?

Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid via PCR, often supported by brain biopsy. Early recognition is critical because Tysabri dosing should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.